Table 1 Characteristics of all patients, and according to overall cognitive impairment status at year 2
Characteristics | Patients (n = 200) | Patients with overall impairment at year 2 (n = 53) | Patients without overall impairment at year 2 (n = 146) | p |
|---|---|---|---|---|
Demographics | ||||
Age, mean years (SD) [range] | 53.5 (11) [28–83] | 58.1 (10) [35–81] | 51.9 (11) [28–83] |  < 0.001 |
Education, mean years (SD) [range] | 13.2 (2.8) [5–20] | 11.7 (2.7) [5–20] | 13.8 (2.6) [9–20] |  < 0.001 |
Clinical | ||||
ECOG, No. (%) | 1 | |||
 0 | 185 (97) | 49 (98) | 136 (97) |  |
 1 ≤  | 5 (3) | 1 (2) | 4 (3) |  |
 Missing | 10 (5) | 2 (3.8) | 8 (5.6) |  |
Charlson, No. (%) | Â | Â | Â | 0.05 |
 0 | 148 (78) | 33 (67) | 114 (82) |  |
 1 ≤  | 41 (22) | 16 (33) | 25 (18) |  |
 Missing | 11 (5.5) | 4 (7.5) | 7 (4.9) |  |
Psychotropic medications, No. (%) | 15 (8) | 5 (9) | 10 (7) | 0.76 |
BMI, mean (SD) | 26.0 (5.2) | 27.5 (5.8) | 25.5 (4.9) | 0.03 |
Cancer stage, No. (%) | Â | Â | Â | 0.07 |
 Stage I | 85 (43) | 27 (51) | 57 (39) |  |
 Stage II | 83 (42) | 17 (32) | 66 (46) |  |
 Stage III | 30 (15) | 9 (14) | 21 (15) |  |
 Missing | 2 (1) | 0 (0) | 2 (1.4) |  |
Grade, No. (%) | Â | Â | Â | 0.35 |
 I | 29 (15) | 10 (20) | 19 (13) |  |
 II | 105 (53) | 28 (55) | 76 (52) |  |
 III | 63 (32) | 13 (25) | 50 (34) |  |
 Missing | 3 (1.5) | 1 (1.9) | 2 (1.4) |  |
HER2-Positive, No. (%) | 25 (13) | 7 (13) | 18 (12) | 1 |
 Negative | 174 (87) | 45 (87) | 128 (88) |  |
 Missing | 1 (0.5) | 1 (1.9) | 0 (0) |  |